Plasma tetranectin as a potential clinical biomarker for epilepsy and correlation with clinical and social characteristics

International Journal of Epilepsy - Tập 4 - Trang 2-5 - 2017
Ekta Singh Dahiya1, Man Mohan Mehndiratta2, Krishna Kolappa Pillai1
1Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi, 110062, India
2Department of Neurology, Govind Ballabh Pant Hospital, New Delhi, 110002, India

Tóm tắt

Abstract Background Tetranectin concentration has been identified as a biomarker of several types of metastatic and malignant cancers. The role of tetranectin has also be seen in some neurological disorders. We aimed to estimate the plasma tetranectin concentration in different groups of people with epilepsy (PWE) followed-up for a year. As a secondary objective, the clinical and social characteristics were also correlated with the tetranectin levels. Methods We enrolled 90 subjects grouped as Newly-diagnosed epilepsy (NDE), Drug-effective epilepsy (DEE), and Drug-refractory epilepsy (DRE) and an age-gender matched control group (n = 30). The plasma samples were collected thrice at the six-month interval and were analysed for the tetranectin concentration using S-ELISA. Results The mean plasma tetranectin levels at the baseline test were significantly lower for the DEE (6.294 ± 0.806) and DRE (7.572 ± 0.545) groups compared with control group (9.71 ± 0.628) but not the NDE group (8.651 ± 0.859 vs. 9.71 ± 0.628; p > 0.05). On a year of follow-up, the tetranectin levels for the NDE group significantly decreased (p < 0.001) matching with that of the DEE and DRE group. Multivariate linear regression analysis showed that gender (p = 0.035) in the DRE group and seizure type (p = 0.040) and diet (p = 0.046) for the NDE group were significantly correlated. Conclusion The plasma tetranectin level in PWE significantly decreased as the disease progressed irrespective of the stage of epilepsy. Thus, tetranectin could be considered as a potential progressive biomarker for epilepsy. The study outcome suggests further investigation for the possible link of tetranectin levels with clinical and social parameters.

Tài liệu tham khảo

Berg, 2010, Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009, Epilepsia, 51, 676, 10.1111/j.1528-1167.2010.02522.x Joseph, 2013, Pattern of seizure cases in tertiary care hospitals in Karnataka state of India, Ann Indian Acad Neurol, 16, 347, 10.4103/0972-2327.116925 De Boer, 2008, The global burden and stigma of epilepsy, Epilepsy Behav, 12, 540, 10.1016/j.yebeh.2007.12.019 Sridharan, 1999, Prevalence and pattern of epilepsy in India, Epilepsia, 40, 631, 10.1111/j.1528-1157.1999.tb05566.x Bharucha, 2012, Epidemiology and treatment gap of epilepsy in India, Ann Indian Acad Neurol, 15, 352, 10.4103/0972-2327.104360 Engel, 2011, Biomarkers in epilepsy: introduction, Biomark Med, 5, 537, 10.2217/bmm.11.62 Clemmensen, 1986, Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin, Eur J Biochem, 156, 327, 10.1111/j.1432-1033.1986.tb09586.x Fuhlendorff, 1987, Primary structure of tetranectin, a plasminogen kringle 4 binding plasma protein: homology with asialoglycoprotein receptors and cartilage proteoglycan core protein, Biochemistry, 26, 6757, 10.1021/bi00395a027 Arellano-Garcia, 2010, Identification of tetranectin as a potential biomarker for metastatic oral cancer, Int J Mol Sci, 11, 3106, 10.3390/ijms11093106 Høgdall, 1998, Human tetranectin: methodological and clinical studies, APMIS, 106, 7, 10.1111/j.1600-0463.1998.tb05659.x Wang, 2010, Tetranectin is a potential biomarker in cerebrospinal fluid and serum of patients with epilepsy, Clin Chim Acta, 411, 581, 10.1016/j.cca.2010.01.022 Wang, 2010, Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson’s disease, Acta Neurol Scand, 122, 350 Xiao, 2009, Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy, Brain Res, 1255, 180, 10.1016/j.brainres.2008.12.008 Stoevring, 2005, Tetranectin in cerebrospinal fluid: biochemical characterisation and evidence of intrathecal synthesis or selective uptake into CSF, Clin Chim Acta, 359, 65, 10.1016/j.cccn.2005.03.034 Mrabet, 2004, Health-related quality of life of people with epilepsy compared with a general reference population: a Tunisian study, Epilepsia, 45, 838, 10.1111/j.0013-9580.2004.56903.x Rajabi, 2009, Quality of life of Epileptic Patients Compared to General, Acta Med Iran, 47, 75 Mbizvo, 2012, Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review, Cochrane Database Syst Rev, 12, 10.1002/14651858.CD001901.pub2 Marson, 2001, Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review, Epilepsy Res, 46, 259, 10.1016/S0920-1211(01)00287-X Koshy, 2004, Frequent seizures and polytherapy impair quality of life in persons with epilepsy, Neurol Asia, 9, 142 Kumari, 2009, Stigma and quality of life in individuals with epilepsy: a preliminary report, Epilepsy Behav, 15, 358, 10.1016/j.yebeh.2009.05.003 Sinha, 2011, Factors associated with quality of life of patients with epilepsy attending a tertiary care hospital in Kolkata, India, Neurol Asia, 16 Basu, 2008, Psychometric properties of Bengali version of QOLIE-10 in epileptic patients, Ann Indian Acad Neurol, 11, 28, 10.4103/0972-2327.40222
Thông tin
Thông tin xuất bản

International Journal of Epilepsy

Tập 4

2-5

Thông tin tác giả